Enabling Therapeutic Drug Monitoring from Home through Dried Blood Spot (DBS) Sampling
| Reference number | |
| Coordinator | KTH HOLDING AKTIEBOLAG |
| Funding from Vinnova | SEK 1 989 000 |
| Project duration | January 2016 - August 2017 |
| Status | Completed |
Important results from the project
The overall goal of the project has been to create an operational entrepreneurial company with a first product ready to be sold to an identified customer or a set of customers. Now, as the project ended, we can see that both the purpose and the goal have been met and to some extent also been exceeded.
Expected long term effects
At the start of the project we had the following goals: 1) Have a first complete product that works for users and was supported by clinical data. 2) A company been formed, the business plan been prepared and be ready for further funding. An IPR strategy selected and blood and plasma patents accordingly secured. 3) Developed and tested a scalable production and packaging method. Selected, prepared and linked our first paying customer. 4) Ready to sell and have a plan to increase sales. We can proudly say that all goals are fulfilled and certain goals have been largely exceeded.
Approach and implementation
The four stages of the project have been divided into four areas: business / customer / funding, manufacturing, regulatory, and IPR. During stage 1, the focus was on finding the customer and understanding customer needs, developing a first prototype for customers as well as securing IP. During stage 2, work continued on finding a suitable customer, prototypes got validated in preclinical studies and contacts taken with investors. In stage 3, regulatory work and investors were worked with and stage 4 was aimed at having a finished prototype and processing first paying customer.